Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals has presented Phase 2 clinical data for azetukalner (XEN1101) in major depressive disorder (MDD) at the ASCP 2024 Annual Meeting.
Key findings include a meaningful reduction in depression and early onset of action, with a significant reduction in anhedonia. Though a 3.04 MADRS score difference between placebo and 20 mg azetukalner was observed, it was not statistically significant (P=0.135). Significant differences were noted in HAM-D17 (P=0.042) and SHAPS scores (P=0.046).
Azetukalner was well tolerated with no serious adverse events reported. Common TEAEs included dizziness (17.9%), somnolence (10.7%), headache (8.9%), and disturbance in attention (8.9%). Discontinuation rates were low.
The company aims to initiate Phase 3 trials in late 2024.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) reported financial results for Q1 2024 and provided a corporate update. The company received approval for the use of 'azetukalner' as the nonproprietary name for XEN1101. Progress continues in the epilepsy program, with Phase 3 expected to start in MDD in the second half of 2024. Financially, Xenon has cash to fund operations into 2027.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the BofA Securities Health Care Conference 2024. The presentation will take place on May 15, 2024, in Las Vegas, NV, featuring the company's President, CEO, and CFO. The webcast will be available on the company's website for replay. Xenon is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for neurological and psychiatric disorders, such as epilepsy and depression.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 2024 RBC Capital Markets Global Healthcare Conference. The event will take place on May 14-15, 2024, in New York, NY. Presenters include Ian Mortimer, President and CEO, and Sherry Aulin, CFO. The company focuses on neuroscience, aiming to develop therapeutics for neurological and psychiatric disorders. Xenon's live webcast will be available on their website for replay.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2024 financial results on May 9, 2024. The company focuses on neuroscience and aims to develop innovative therapeutics for neurological and psychiatric disorders. Xenon encourages participants to pre-register for the conference call/webcast to discuss the results. The company is committed to addressing high unmet medical needs in areas such as epilepsy and depression.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
